Last-Resort drug opens door for transplant patients with rare blood clotting complication
Disease control
APPROVED_FOR_MARKETING
This program gives patients who have had a stem cell transplant and developed a serious blood clotting condition (HSCT-TMA) access to an experimental drug called narsoplimab. The goal is to control the disease when no other options are available. Adults and children who meet the …
Sponsor: Omeros Corporation • Aim: Disease control
Last updated May 15, 2026 11:56 UTC